

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
19 September 2024 (19.09.2024)



(10) International Publication Number
WO 2024/191675 A1

(51) International Patent Classification:

C07D 209/52 (2006.01) C07D 487/04 (2006.01)
C07D 403/12 (2006.01) A61P 25/02 (2006.01)
C07D 413/12 (2006.01) A61P 29/00 (2006.01)
C07D 471/04 (2006.01) A61K 31/403 (2006.01)

(21) International Application Number:

PCT/US2024/018591

(22) International Filing Date:

06 March 2024 (06.03.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/489,556 10 March 2023 (10.03.2023) US

(71) Applicant: **ELI LILLY AND COMPANY** [US/US]; Lilly
Corporate Center, Indianapolis, Indiana 46285 (US).

(72) Inventors: **COATES, David Andrew**; c/o Eli Lilly
and Company, P. O. Box 6288, Indianapolis, Indiana
46206-6288 (US). **FILLA, Sandra Ann**; c/o Eli Lil-
ly and Company, P.O. Box 6288, Indianapolis, Indiana
46206-6288 (US). **REMICK, David Michael**; c/o Eli Lil-
ly and Company, Indianapolis, Indiana 46206-6288 (US).
RIZZO, John Robert; c/o Eli Lilly and Company, P.O.
Box 6288, Indianapolis, Indiana 46206-6288 (US). **TENG,**
Jing; c/o Eli Lilly and Company, P.O. Box 6288, Indianapo-
lis, Indiana 46206-6288 (US).

(74) Agent: **MCCRARY, Parker D.** et al.; Eli Lilly and Compa-
ny, P.O. Box 6288, Indianapolis, Indiana 46206-6288 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,

GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a
patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the
earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))

(54) Title: METHODS FOR THE PREPARATION OF SSTR4 AGONISTS AND SALTS THEREOF

(57) Abstract: Method for preparing SSTR4 agonist compounds. Method for preparing SSTR4 agonist compounds through a di-
asteromerically selective cyclization reaction without the need for a separate epimerization step. Novel intermediates for preparing
SSTR4 agonist compounds. Novel salts of certain SSTR4 agonists, such as (1*R*,5*S*,6*r*)-*N*-(2-(1-Methyl-1*H*-indazol-3-yl)propan-2-
yl)-3-azabicyclo[3.1.0]hexane-6-carboxamide succinate and as (1*R*,5*S*,6*r*)-*N*-(2-(1-Methyl-1*H*-indazol-3-yl)propan-2-yl)-3-azabicy-
clo[3.1.0]hexane-6-carboxamide adipate. Methods of treatment of pain, such as osteoarthritic, neuropathic, and lower back pain through
the administration of certain SSTR4 agonists and pharmaceutically acceptable salts thereof.



WO 2024/191675 A1